Free Trial
NASDAQ:CLYM

Climb Bio (CLYM) Stock Price, News & Analysis

Climb Bio logo
$1.17 +0.02 (+1.74%)
As of 04:00 PM Eastern

About Climb Bio Stock (NASDAQ:CLYM)

Key Stats

Today's Range
$1.09
$1.20
50-Day Range
$1.15
$1.99
52-Week Range
$1.09
$11.55
Volume
565,367 shs
Average Volume
358,017 shs
Market Capitalization
$78.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Strong Buy

Company Overview

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Remove Ads

Climb Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

CLYM MarketRank™: 

Climb Bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 417th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Climb Bio has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Climb Bio has received no research coverage in the past 90 days.

  • Read more about Climb Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Climb Bio is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Climb Bio is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Climb Bio has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Climb Bio's valuation and earnings.
  • Short Interest

    There is no current short interest data available for CLYM.
  • Dividend Yield

    Climb Bio does not currently pay a dividend.

  • Dividend Growth

    Climb Bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CLYM.
  • News Sentiment

    Climb Bio has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Climb Bio this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for CLYM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,571.00 in company stock.

  • Percentage Held by Insiders

    Only 3.20% of the stock of Climb Bio is held by insiders.

  • Percentage Held by Institutions

    69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Climb Bio's insider trading history.
Receive CLYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter.

CLYM Stock News Headlines

Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board
What is Leerink Partnrs' Forecast for Climb Bio Q2 Earnings?
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

CLYM Stock Analysis - Frequently Asked Questions

Climb Bio's stock was trading at $1.80 at the start of the year. Since then, CLYM shares have decreased by 35.0% and is now trading at $1.17.
View the best growth stocks for 2025 here
.

Climb Bio, Inc. (NASDAQ:CLYM) posted its quarterly earnings data on Tuesday, March, 25th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02.

Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/25/2025
Today
4/04/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLYM
Previous Symbol
NASDAQ:CLYM
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+769.6%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
0.29

Miscellaneous

Free Float
65,073,000
Market Cap
$77.60 million
Optionable
N/A
Beta
-0.10
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CLYM) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners